The firm represents Valtech Cardio in its acquisition by HeartWare, a combination that will help deliver transformative products to patients with advanced heart failure and degenerative heart conditions.
On September 1, it was announced that Willkie client Valtech Cardio has agreed to be acquired by HeartWare International. The combined company will offer clinical heart failure teams a compelling portfolio of surgical and interventional technologies to serve the heart failure population.
Israel-based Valtech is a privately held company specializing in the development of devices for mitral and tricuspid valve repair and replacement, the most prevalent heart valve diseases. U.S.-based HeartWare (Nasdaq: HTWR) is a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure.
The Willkie deal team included partners Morgan Elwyn, Thomas Mark, Eugene Chang and Christopher Peters, and associates Ziyad Aziz, and Jonathan Kubek.